Why did Gland Pharma (GLAND) stock move recently?

On 7/29/2026, Gland Pharma moved +4.8% — Gland Pharma received USFDA approval for generic Sugammadex Injection (bioequivalent to Bridion), announced via BSE press release today, driving the stock higher. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Gland Pharma (GLAND) overvalued or fairly valued?

MarketChacha shows Gland Pharma's valuation in context — a forward P/E of about 30.5, a price-to-book of about 4.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Gland Pharma's revenue?

Gland Pharma reported revenue of ₹4,552 Cr for FY2026, with net profit of ₹1,300 Cr, per official filings.

What is the share price of Gland Pharma (GLAND)?

Gland Pharma last traded at ₹2,939.70 (+1.1% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Gland Pharma

GLAND · NSE · Pharma · India

Snapshot

TickerGLAND

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees4,332

HeadquartersHyderabad, India

Websitewww.glandpharma.com

Filings tracked13

About Gland Pharma

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, and neurological and central nervous system; blood related, ophthalmics and otologicals, cardiac, gastro-intestinal, and hormonal products; pain, neuromuscular blocking agents, and analgesics; respiratory and pulmonology; and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier preparation, and technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Who owns it

Promoters51.8%
Institutions32.8%
Public & other15.5%

70 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

Margin has compressed by about 5.6 points over the period — profitability is trending down.

Net margin trend21.5% → 16.0%

Margin has compressed by about 5.6 points over the period — profitability is trending down.

Growth qualityrev 15% · PAT 7%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹1,933 Cr · EPS 19.91

Est. earnings growth +17.3%

Next fiscal year

Rev ₹8,584 Cr · EPS 96.42

Est. earnings growth +20.6%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹6,431 Cr

Net margin

16.0%

Revenue CAGR (3y)

+21.1%

Profit CAGR (3y)

+9.6%

Net profit (FY2026)

₹1,027 Cr

Ask MarketChacha about GLAND

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 29, 2026
Gland Pharma received USFDA approval for generic Sugammadex Injection (bioequivalent to Bridion), announced via BSE press release today, driving the stock higher.
source 1 ↗source 2 ↗source 3 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

On MarketChacha

Posts about GLAND

c/india-daily · 8/10/2026▲ 0

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹6,431 Cr	₹1,027 Cr	16.0%
FY2025	₹5,617 Cr	₹699 Cr	12.4%
FY2024	₹5,665 Cr	₹772 Cr	13.6%
FY2023	₹3,625 Cr	₹781 Cr	21.5%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹1,800 Cr	₹317 Cr	17.6%
Q4 FY26	₹1,743 Cr	₹367 Cr	21.0%
Q3 FY26	₹1,695 Cr	₹261 Cr	15.4%
Q2 FY26	₹1,487 Cr	₹184 Cr	12.4%
Q1 FY26	₹1,506 Cr	₹215 Cr	14.3%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
48th AGM Voting Results along with Scrutinizers Report
BSE8/26/2026material
Shareholder Meeting / Postal Ballot-Outcome of AGM
48th AGM Outcome
BSE8/25/2026material
Earnings Call Transcript
Q1FY27 Earnings Call Transcript
BSE8/17/2026
Change in Management
Appointment of Chief Executive Officer of the Company
BSE8/14/2026
Press Release / Media Release
Gland Pharma announces strategic CDMO partnership with a Global Pharmaceutical Company
BSE8/9/2026
Letter To Shareholders
Letter to Shareholders regarding dispatch of 48th AGM Notice and Annual report for the FY 2025-26
BSE7/31/2026
Business Responsibility and Sustainability Reporting (BRSR)
BRSR Report for the year ended March 31, 2026
BSE7/31/2026
Reg. 34 (1) Annual Report.
Annual Report for the FY 2025-26
BSE7/31/2026
Notice Of 48Th AGM
Notice of 48th AGM
BSE7/31/2026material
Allotment of ESOP / ESPS
Allotment of Equity Shares under ESOPS
BSE7/30/2026
Issue of Securities
Grant of Stock Options under Gland Pharma Employee Stock Option Scheme, 2025
BSE7/30/2026
Press Release / Media Release
Gland Pharma receives approval for Suggamadex Injection
BSE7/29/2026
Board Meeting Intimation for Declaration Of Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30, 2026
Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Unaudited Standalone and Consolidated ....
BSE7/24/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.